Drugs /

axalimogene filolisbac

Back to Drugs List

Overview

NCI Definition [1]:
A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.

Clinical Trials

View Clinical Trials for axalimogene filolisbac

Axalimogene filolisbac has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating axalimogene filolisbac, 2 are phase 2 (2 open) and 1 is phase 3 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for axalimogene filolisbac clinical trials.

Cervical adenocarcinoma, cervical adenosquamous carcinoma, and cervical squamous cell carcinoma are the most common diseases being investigated in axalimogene filolisbac clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Axalimogene Filolisbac
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating axalimogene filolisbac and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
lm-llo-e7, adxs11-001, adxs11-001 vaccine, attenuated live listeria encoding human papilloma virus 16 e7 vaccine, lovaxin c, live-attenuated listeria monocytogenes cancer vaccine adxs11-001, lovaxin-c, attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001, attenuated live listeria encoding hpv 16 e7 vaccine
NCIT ID [1]:
C74595

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.